Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype
- PMID: 28767130
- DOI: 10.1111/nan.12428
Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype
Abstract
Aims: Glioblastomas are highly aggressive and treatment resistant. Increasing evidence suggests that tumour-associated macrophages/microglia (TAMs) facilitate tumour progression by acquiring a M2-like phenotype. Our objective was to investigate the prognostic value of TAMs in gliomas using automated quantitative double immunofluorescence.
Methods: Samples from 240 patients with primary glioma were stained with antibodies against ionized calcium-binding adaptor molecule-1 (IBA-1) and cluster of differentiation 204 (CD204) to detect TAMs and M2-like TAMs. The expression levels were quantified by software-based classifiers. The associations between TAMs, gemistocytic cells and glioblastoma subtype were examined with immuno- and haematoxylin-eosin stainings. Three tissue arrays containing glioblastoma specimens were included to study IBA-1/CD204 levels in central tumour and tumour periphery and to characterize CD204+ cells.
Results: Our data revealed that the amount of especially CD204+ TAMs increases with malignancy grade. In grade III-IV, high CD204 expression was associated with shorter survival, while high IBA-1 intensity correlated with a longer survival. In grade IV, CD204 showed independent prognostic value when adjusting for clinical data and the methylation status of O6-methylguanine-DNA methyltransferase. Our findings were confirmed in two bioinformatics databases. TAMs were more abundant in central tumour tissue, mesenchymal glioblastomas and gliomas with many gemistocytic cells. CD204+ TAMs co-expressed proteins related to tumour aggressiveness including matrix metallopeptidase-14 and hypoxia-inducible factor-1α.
Conclusions: This is the first study to use automated quantitative immunofluorescence to determine the prognostic impact of TAMs. Our results suggest that M2-like TAMs hold an unfavourable prognostic value in high-grade gliomas and may contribute to a pro-tumourigenic microenvironment.
Keywords: CD204; glioblastoma; glioma; macrophages; microglia; prognosis.
© 2017 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.
Similar articles
-
Tumour-associated CD204+ microglia/macrophages accumulate in perivascular and perinecrotic niches and correlate with an interleukin-6-enriched inflammatory profile in glioblastoma.Neuropathol Appl Neurobiol. 2022 Feb;48(2):e12772. doi: 10.1111/nan.12772. Epub 2022 Jan 5. Neuropathol Appl Neurobiol. 2022. PMID: 34713474 Free PMC article.
-
Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.J Pathol. 2008 Sep;216(1):15-24. doi: 10.1002/path.2370. J Pathol. 2008. PMID: 18553315
-
Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression.Neuro Oncol. 2017 May 1;19(5):648-659. doi: 10.1093/neuonc/now251. Neuro Oncol. 2017. PMID: 28453746 Free PMC article.
-
The neuropathological basis to the functional role of microglia/macrophages in gliomas.Neurol Sci. 2017 Sep;38(9):1571-1577. doi: 10.1007/s10072-017-3002-x. Epub 2017 Jun 7. Neurol Sci. 2017. PMID: 28593528 Review.
-
When Immune Cells Turn Bad-Tumor-Associated Microglia/Macrophages in Glioma.Int J Mol Sci. 2018 Feb 1;19(2):436. doi: 10.3390/ijms19020436. Int J Mol Sci. 2018. PMID: 29389898 Free PMC article. Review.
Cited by
-
Systemic and local immunosuppression in glioblastoma and its prognostic significance.Front Immunol. 2024 Feb 28;15:1326753. doi: 10.3389/fimmu.2024.1326753. eCollection 2024. Front Immunol. 2024. PMID: 38481999 Free PMC article. Review.
-
Current state of immune checkpoints therapy for glioblastoma.Heliyon. 2024 Jan 13;10(2):e24729. doi: 10.1016/j.heliyon.2024.e24729. eCollection 2024 Jan 30. Heliyon. 2024. PMID: 38298707 Free PMC article. Review.
-
Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy.Front Immunol. 2024 Jan 11;14:1299064. doi: 10.3389/fimmu.2023.1299064. eCollection 2023. Front Immunol. 2024. PMID: 38274827 Free PMC article. Review.
-
Limited Effects of Class II Transactivator-Based Immunotherapy in Murine and Human Glioblastoma.Cancers (Basel). 2023 Dec 30;16(1):193. doi: 10.3390/cancers16010193. Cancers (Basel). 2023. PMID: 38201622 Free PMC article.
-
An engineered glioblastoma model yields novel macrophage-secreted drivers of invasion.bioRxiv [Preprint]. 2023 Nov 19:2023.11.18.567683. doi: 10.1101/2023.11.18.567683. bioRxiv. 2023. PMID: 38014161 Free PMC article. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
